# Paxlovid for Treatment of Long Covid

> **NCT05576662** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 168 (actual)

## Conditions studied

- Post-acute Sequelae of SARS-CoV-2 Infection
- Long COVID

## Interventions

- **DRUG:** Nirmatrelvir
- **DRUG:** Placebo
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT05576662
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-08
- **Primary completion:** 2023-08-14
- **Final completion:** 2023-09-12
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576662, "Paxlovid for Treatment of Long Covid". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05576662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*